CN103467554A - 药学固体形式 - Google Patents

药学固体形式 Download PDF

Info

Publication number
CN103467554A
CN103467554A CN2013102558234A CN201310255823A CN103467554A CN 103467554 A CN103467554 A CN 103467554A CN 2013102558234 A CN2013102558234 A CN 2013102558234A CN 201310255823 A CN201310255823 A CN 201310255823A CN 103467554 A CN103467554 A CN 103467554A
Authority
CN
China
Prior art keywords
compound
ethynyl
isoallopregnane
etioallocholane
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013102558234A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·K·怀特
德怀特·斯蒂克尼
埃林·奥尔松
基斯·R·罗里梅尔
布伦登·S·沃尔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbor Therapeutics Inc
Original Assignee
Harbor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbor Therapeutics Inc filed Critical Harbor Therapeutics Inc
Publication of CN103467554A publication Critical patent/CN103467554A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CN2013102558234A 2008-02-05 2009-02-05 药学固体形式 Pending CN103467554A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2647208P 2008-02-05 2008-02-05
US61/026,472 2008-02-05
US9369408P 2008-09-02 2008-09-02
US61/093,694 2008-09-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200980104255XA Division CN101939009B (zh) 2008-02-05 2009-02-05 药学固体形式

Publications (1)

Publication Number Publication Date
CN103467554A true CN103467554A (zh) 2013-12-25

Family

ID=40952461

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2013102558234A Pending CN103467554A (zh) 2008-02-05 2009-02-05 药学固体形式
CN200980104255XA Expired - Fee Related CN101939009B (zh) 2008-02-05 2009-02-05 药学固体形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200980104255XA Expired - Fee Related CN101939009B (zh) 2008-02-05 2009-02-05 药学固体形式

Country Status (10)

Country Link
US (4) US8518922B2 (cg-RX-API-DMAC7.html)
EP (1) EP2249838A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011511011A (cg-RX-API-DMAC7.html)
KR (1) KR20100113602A (cg-RX-API-DMAC7.html)
CN (2) CN103467554A (cg-RX-API-DMAC7.html)
AU (1) AU2009212314C1 (cg-RX-API-DMAC7.html)
CA (1) CA2712005C (cg-RX-API-DMAC7.html)
EA (1) EA018974B9 (cg-RX-API-DMAC7.html)
IL (1) IL207378A0 (cg-RX-API-DMAC7.html)
WO (1) WO2009100258A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE049642T2 (hu) 2007-12-07 2020-09-28 Vertex Pharma 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)-ciklopropánkarboxamido)-3-metilpiridin-2-il)-benzoesav szilárd formái
CA2728889C (en) * 2008-04-03 2016-06-14 Harbor Biosciences, Inc. Solid state forms of a pharmaceutical
WO2011066582A1 (en) * 2009-11-30 2011-06-03 Harbor Biosciences, Inc. Anticancer compounds and screening method
EP2524059A4 (en) 2010-01-13 2013-11-20 Caris Life Sciences Luxembourg Holdings DETECTION OF GASTROINTESTINAL DISEASES
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
AU2011343599A1 (en) * 2010-12-17 2013-05-09 Harbor Biosciences, Inc. Steroid tetrol solid state forms
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CN104173353B (zh) * 2013-05-22 2018-08-21 中国医药工业研究总院 不含表面活性剂的固体制剂及其制备方法
CA2930199C (en) * 2013-11-12 2022-10-25 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
CN105434444B (zh) * 2014-09-29 2021-02-05 上海奥奇医药科技有限公司 一种A-失碳-5α雄甾烷化合物的口服制剂
RU2017112748A (ru) 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. Композиции онапристона пролонгированного действия и способы
AU2016326657B2 (en) 2015-09-25 2019-10-24 Context Biopharma, Inc. Methods of making onapristone intermediates
HK1255104A1 (zh) 2015-12-15 2019-08-02 Context Biopharma Inc. 无定形的奥那司酮组合物及其制备方法
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection
DK3601265T3 (da) * 2017-03-30 2023-09-18 Merck Patent Gmbh Fast form af (s)-[2-chlor-4-fluor-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
RU2668526C1 (ru) * 2017-08-18 2018-10-01 Федеральное государственное бюджетное учреждение "Информационно-методический центр по экспертизе, учету и анализу обращения средств медицинского применения" Федеральной службы по надзору в сфере здравоохранения Способ идентификации и последующего количественного определения основных компонентов в инъекционных лекарственных средствах
KR20210111254A (ko) 2018-11-30 2021-09-10 캐리스 엠피아이, 아이엔씨. 차세대 분자 프로파일링
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
IL293489A (en) 2019-12-02 2022-08-01 Caris Mpi Inc predictor of pan-cancer platinum response
MX2022009999A (es) 2020-02-14 2023-01-19 Caris Mpi Inc Puntuacion de prevalencia genomica panomica.
US20260157968A1 (en) * 2024-12-11 2026-06-11 Americana Pharma Llc Method and Composition for an Improved Bioavailability Delivery System

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567830A (en) * 1994-02-14 1996-10-22 Cocensys, Inc. Process for synthesis of acetylenic carbinols
US20070129548A1 (en) * 2005-12-07 2007-06-07 Lushi Tan Polymorphs of an androgen receptor modulator
US20080021006A1 (en) * 1999-09-30 2008-01-24 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical Compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE681869C (de) * 1935-11-22 1939-10-03 Schering Ag Verfahren zur Darstellung von tertiaeren Alkoholen der Cyclopentanopolyhydrophenanthrenreihe
CH202847A (de) 1937-06-26 1939-02-15 Chem Ind Basel Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe.
WO1994005630A1 (en) 1992-08-28 1994-03-17 Lunar Corporation 1α,24(S)-DIHYDROXY VITAMIN D2, ITS FORMATION AND USE
PT889889E (pt) 1996-03-29 2007-01-31 Duphar Int Res Composto de piperazina e piperidina
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
US7045513B1 (en) 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
EP1591121B1 (en) 2000-12-14 2009-06-24 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Process for preparing steroid hormone products comprising a stabilizing agent in non-crystalline form
AR034206A1 (es) 2001-02-16 2004-02-04 Solvay Pharm Bv Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos
DE10314610A1 (de) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
US7540016B2 (en) * 2004-07-21 2009-05-26 Beachhead Solutions, Inc. System and method for lost data destruction of electronic data stored on a portable electronic device which communicates with servers that are inside of and outside of a firewall
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
TWI305979B (en) * 2006-03-24 2009-02-01 Hon Hai Prec Ind Co Ltd Wireless transceiving system
CN103211821A (zh) * 2006-04-22 2013-07-24 霍利斯—伊登医药公司 药物和用途
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567830A (en) * 1994-02-14 1996-10-22 Cocensys, Inc. Process for synthesis of acetylenic carbinols
US20080021006A1 (en) * 1999-09-30 2008-01-24 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical Compositions
US20070129548A1 (en) * 2005-12-07 2007-06-07 Lushi Tan Polymorphs of an androgen receptor modulator

Also Published As

Publication number Publication date
KR20100113602A (ko) 2010-10-21
US9314471B2 (en) 2016-04-19
CN101939009A (zh) 2011-01-05
EA201070713A1 (ru) 2011-08-30
AU2009212314A1 (en) 2009-08-13
US20090291932A1 (en) 2009-11-26
EA018974B1 (ru) 2013-12-30
US8518922B2 (en) 2013-08-27
CA2712005C (en) 2014-04-15
US20130338125A1 (en) 2013-12-19
WO2009100258A1 (en) 2009-08-13
EP2249838A1 (en) 2010-11-17
IL207378A0 (en) 2010-12-30
EA018974B9 (ru) 2014-04-30
CA2712005A1 (en) 2009-08-13
CN101939009B (zh) 2013-07-17
JP2011511011A (ja) 2011-04-07
HK1147695A1 (en) 2011-08-19
AU2009212314B2 (en) 2013-11-21
EP2249838A4 (en) 2012-05-02
AU2009212314C1 (en) 2014-05-08
US20130345184A1 (en) 2013-12-26
US20130345455A1 (en) 2013-12-26

Similar Documents

Publication Publication Date Title
US8518922B2 (en) Pharmaceutical solid state forms
JP6946194B2 (ja) キナーゼを調節する化合物の固体形態
Saif et al. A phase 1, dose-escalation, pharmacokinetic and pharmacodynamic study of BIIB021 administered orally in patients with advanced solid tumors
WO2024050396A1 (en) Methods of treating solid tumors having activating fgfr3 gene alterations
Yap et al. First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies
US20220265654A1 (en) Dosage regimens for parp7 inhibitors
JP2006505564A (ja) Sarmによる高齢男性のアンドロゲン減少に関連する病気の治療
US7045513B1 (en) DHEA composition and method
AU779138B2 (en) DHEA composition and method
CN110563644A (zh) 一种仑伐替尼甲磺酸盐的新晶型
WO2023275248A1 (en) A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product
JP2017511367A (ja) 1−エチル−7−(2−メチル−6−(1H−1,2,4−トリアゾール−3−イル)ピリジン−3−イル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オン及び共形成物を含む固体形態、その組成物及び使用方法
WO2023212071A1 (en) Combination and the use thereof
Mallik et al. A Subtype-specific Probe for Estrogen Receptor Alpha (ERα) Reveals Imaging of PROTAC-induced Degradation
HK1147695B (en) Pharmaceutical solid state forms
WO2023205795A1 (en) Combination therapy using a substituted pyrimidin-4(3h)-one and nivolumab as well as its use in the treatment of cancer
CN120035437A (zh) 用于治疗EGFR突变癌症的N-(1-((R)-1-丙烯酰基氮杂环庚烷-3-基)-7-氯-6-(((R)-四氢呋喃-3-基)氧基)-1H-苯并[d]咪唑-2-基)-2-甲基异烟酰胺(NX-019)
WO2024245340A1 (zh) Csf-1r抑制剂药物组合物,其制备方法和在药学上的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131225